Product Compliance And Certification For Medical Device In Taiwan

Scope and evidence must be confirmed before any paid tests or filings.

Taiwan product-route map: conventional medical devices, IVDs, software and combined systems

A Taiwan medical device does not receive one universal ‘certification’. First establish whether the product meets the Medical Devices Act definition and its precise TFDA classification item. Then map product authorization, manufacturer quality documentation, the Taiwanese dealer/importer, labeling, and any independent radio or distribution controls. A foreign CE mark or US clearance is useful evidence, not a substitute for Taiwan's route.

This page addresses the cross-regime decision for the complete product, including non-wearable devices, reagents, standalone medical software and systems. Sensor placement, consumer wearables and body-worn connectivity require a more focused assessment on the linked wearable-device page.

Use Taiwan’s device definition and TFDA risk classes

TFDA looks at intended use, indications, operating principle and the classification annex—not only the device's appearance or foreign category. Devices are class I (low risk), II (medium) or III (high). Where multiple applicable classifications compete, the highest risk class governs under the classification rules; special accessory, combined-device and device-with-medicine provisions must also be checked.

Medical-purpose software and in-vitro diagnostic reagents can be devices even without a conventional instrument. If no annex item fits, do not assume ‘unregulated’: the rules address classification as class III, subject to the predicate and official-inquiry provisions. Prepare the original IFU, intended-use statement and proposed annex number for a TFDA classification inquiry where uncertainty remains.

A treatment, diagnostic or wellness claim alone does not establish device status. Under Article 3, check the primary intended action and whether it is achieved by means other than pharmacological, immunological, metabolic or chemical action. If a medicine-led or borderline combination product is involved, resolve its legal status before selecting a medical-device license or listing route.

Product-by-product regulatory stack

Product condition / question	Likely regulatory layer	Decision before launch
Diagnosis, treatment, prevention, body-function or conception-control claims	TFDA medical-device status and class I/II/III	Match intended purpose and technology to the classification annex; obtain an official view when unresolved. A medical claim is only a classification trigger: first confirm the product falls within the statutory device definition and its primary mode of action.
Class I item potentially eligible for listing	TFDA listing versus product license	Verify the specifically announced listing item. Class I does not automatically mean listing or exemption.
Item requiring product license, commonly class II/III	TFDA registration and market approval	Determine classification number, product grouping and technical/clinical evidence applicable to the item.
Manufactured abroad; supplied through Taiwan	Foreign-factory QMS/QSD plus licensed local medical-device firm	Check site/product exemptions and the actual QSD or inspection route; appoint a qualified Taiwanese dealer/importer. Under Article 25(3), the importer must be the device-license holder, the firm that completed listing, or a person authorized by either; a general dealer permit alone does not confer those product-specific import rights.
Wholesale/import/export within GDP-designated scope	Dealer GDP system and distribution license	Confirm the designated product and activity and the dealer’s own license before operation.
Built-in Bluetooth, Wi-Fi or other controlled RF function	Potential NCC radio compliance approval, separate from TFDA	Screen exact radio module, antenna, frequency and final integration; do not assume a module approval covers the finished device.
Power supply / electronic parts / other controlled goods	Potential other product-safety or commodity controls	Check item-specific current BSMI/import scope; medical-device status alone neither proves nor disproves applicability.
Specific UDI, import-inspection or advertising triggers	TFDA identification, border inspection and promotional controls	Confirm announcements for this class/product and approve promotional content before publication when required.

Run the classification-to-import sequence

Freeze a single intended-use statement, user type, patient population, action mechanism, sterility, reusable status and final model configuration.
Identify the closest TFDA annex entry and class; search Taiwan-authorized comparators, then use the official inquiry route if classification or device status remains doubtful.
Decide item-by-item whether the route is listing or registration/license; determine whether models may share a submission instead of assuming one authorization for an entire range.
Verify the Taiwanese medical-device firm’s permit, applicant/import rights, manufacturer authorization and foreign-factory QMS/QSD obligations; separately screen GDP scope.
Build the product-specific evidence dossier, Traditional-Chinese label/IFU drafts, and applicable NCC or other parallel approvals for the finished configuration.
Do not import for commercial launch or sell until the applicable approvals/listing and dealer prerequisites are in place; assign renewal, annual listing declaration, adverse-event and change-control ownership.

Do not confuse commercial import with a special-purpose shipment. Medical Devices Act Article 35 permits TFDA to give special approval in defined cases, including investigational devices, samples, certain personal-use shipments and emergencies. This is not automatic permission and does not authorize ordinary commercial sale. Identify the purpose, consignee and approval conditions before arranging shipment.

Build the Taiwan TFDA device-and-importer evidence file

Before asking an agent or laboratory for a fixed route, assemble this evidence index. Individual TFDA submissions vary by classification, announcement and device type; the items below are a scoping checklist, not a claim that every file is mandatory for every class.

Intended use, clinical claim, contraindications, users, care setting, operating principle and product photos.
TFDA classification annex candidate, Taiwan predicate/comparator, model variants and accessory/kit boundaries.
Manufacturer/site identities, site activities, Taiwanese dealer permit, proposed license/listing holder and import authorization.
Original manufacturer IFU, draft Traditional-Chinese IFU/labels, packaging artwork, identifiers and UDI applicability analysis.
Device design, risk management, performance and preclinical testing by relevant technology, including electrical/EMC, sterility, biocompatibility or IVD analytical validation where relevant.
Clinical or scientific performance rationale and test reports; identify Taiwan-specific gaps rather than relying on CE/FDA certificates alone.
Factory QMS/QSD evidence and any available country-of-origin sale certificate and manufacturer authorization required by the chosen route.
For connected products: firmware/software versions, cybersecurity and update controls, RF module and antenna specs, and any NCC test/approval record.

Technical standards, ISO 13485/QMS certificates and test reports are supporting evidence; none by itself replaces a TFDA product license or listing, applicable factory permission or any required distribution license.

Match Taiwan labels to the authorized launch configuration

Article 32 of the Act requires Chinese labeling on the smallest sale package and Chinese instructions before sale, subject to announced or approved exceptions. Implement this for Taiwan using Traditional Chinese; Simplified Chinese text alone is not the appropriate Taiwan labeling solution. Check the approved product name, license/listing number, intended purpose, warnings, holder/manufacturer, model, lot/serial and dating information against the exact authorization.

Treat the label as a reconciliation exercise: the model in the IFU, manufacturer authorization, product registration, QSD scope, import invoice and any NCC certificate must describe a consistent configuration. E-instructions are permitted only for designated devices; advertising has its own approval and claim restrictions. Class-/item-specific UDI or border-inspection notices must be checked rather than presumed universal.

Current TFDA document-control change (effective 1 October 2026): for approved Class II/III registration or change cases, TFDA now publishes the electronically approved label, instructions or packaging version in its license system instead of issuing a paper approved copy. Under the associated electronic-submission pilot, specified supporting originals are uploaded as colour PDFs and retained by the applicant for inspection. Compare the launch artwork with the TFDA's published electronic approval record and notice; this change does not waive the Chinese-label requirement.

For Class II/III label, instructions or packaging changes approved from 1 October 2026, TFDA’s newly published electronic approved version supersedes earlier approved copies. Check the effective approved file, including its electronic seal, against the Taiwan launch artwork in the official TFDA medical-device license database. Do not use an older paper-approved copy as controlling after the new version is published.

Recheck TFDA and NCC scope after product changes

Proposed change	What must be reassessed
New intended use, diagnostic claim or target patient	Reopen device status, classification, evidence sufficiency, labeling and authorization scope.
New factory, outsourced sterilizer, brand or legal holder	Recheck QMS/QSD, authorization holder and whether TFDA approval of changes is required.
New radio module, antenna, firmware or software algorithm	Recheck TFDA safety/performance evidence and NCC scope; record version-specific test decisions.
Changed packaging, shelf-life, model bundle or distribution chain	Check approved labeling, stability/sterility and listing/license particulars; review GDP/UDI duties.

Where wearable-specific analysis begins

This broad product map does not assume every device is wearable. For skin-contact sensing, continuous consumer monitoring, smartwatch claims, radio/battery integration and mobile-app pairing, use the dedicated Taiwan wearable medical-device analysis; this article remains responsible for the full product/regime stack.

Across markets, do not transpose another regulator’s class or certificate: compare intended-use definitions and separate national filings instead.

Questions manufacturers actually face

Is every imported class I device exempt from a TFDA license?

No. Only items announced for listing use that path; other devices need registration/approval. Check the exact annex item and any applicable manufacturing-license exemption separately.

Can a CE certificate or US FDA clearance replace Taiwan approval?

No automatic replacement follows. Foreign approvals, classification references and data can support the dossier, but TFDA rules determine local device status, listing/license, factory and labeling obligations.

Is a diagnostic algorithm without hardware regulated?

It can be: the Act includes software and IVD software where the statutory medical purpose is met. Assess claimed diagnosis, the algorithm’s role, the annex item and whether it has a Taiwan predicate.

Does a Bluetooth medical device need only TFDA approval?

Not necessarily. Assess whether its final radio configuration falls under NCC controlled-RF approval rules; the TFDA product review and NCC radio compliance address different risks.

Can several models be registered under one license?

TFDA guidance allows grouping in defined circumstances, for example same classification number, product name, manufacturer and intended use with model-only differences. Different names or standalone accessories may need separate submissions; confirm before filing.